Jefferies raised the firm’s price target on Pennant Group (PNTG) to $40 from $30 and keeps a Buy rating on the shares. The firm raised its price target to reflect the clearing of the final home health rule overhang, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group initiated with an Outperform at William Blair
- Buy Rating for Pennant Group: Strong Growth Potential and Attractive Valuation
- Pennant Group upgraded to Buy from Hold at Truist
- Wells Fargo says CMS final rule positive for Pennant Group, BrightSpring Health
- CMS announces final rule for home health prospective payment system